norquetiapine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

norquetiapine: metabolite of quetiapine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	11369918
CHEMBL ID	3526391
CHEBI ID	188278
SCHEMBL ID	8311
MeSH ID	M0574371

Synonyms (47)

Synonym
BB 0261035
5747-48-8
FT-0665928
CHEBI:188278
6-piperazin-1-ylbenzo[b][1,4]benzothiazepine
norquetiapine
A8192
11-(piperazin-1-yl)dibenzo[b,f][1,4]thiazepine;11-(1-piperazinyl)dibenzo[b,f][1,4]thiazepine
A25082
dibenzo[b,f][1,4]thiazepine, 11-(1-piperazinyl)-
11-(1-piperazinyl)dibenzo[b,f][1,4]thiazepine
11-(piperazin-1-yl)dibenzo[b,f][1,4]thiazepine
AKOS015854153
SCHEMBL8311
6-piperazin-1-ylbenzo[b][1,5]benzothiazepine
gtpl7545
JLOAJISUHPIQOX-UHFFFAOYSA-N
11-(piperazin-1-yl)-dibenzo[b,f][1,4]thiazepin
11-piperazinyldibenzo[b,f][1,4]thiazepine
11-piperazinyl-dibenzo[b,f][1,4]thiazepine
11piperazinyldibenzo[b,f][1,4]thiazepine
11-piperazinyldibenzo[b,f]-[1,4]-thiazepine
11-piperazin-1-yldibenzo[b,f][1,4]thiazepine
11-piperazin-1-yldibenzo[b,f][1,4]thiazepin
(e)-11-(piperazin-1-yl)dibenzo[b,f][1,4]thiazepine
us8653257, 11-piperazin-1-yl-dibenzo[b,f][1,4]thiazepine
bdbm141313
CHEMBL3526391
unii-v3h1zvv9s6
quetiapine fumarate impurity b [ep impurity]
V3H1ZVV9S6 ,
norquetiapine, analytical standard
W17065
MRF-0000028
CS-0045376
11-piperazin-1-yl-dibenzo[b,f][1,4]thiazepine
SY096658
mfcd09835366
DS-15433
Q27078068
CCG-357082
BCP29749
n-des[2-(2-hydroxyethoxy)ethyl] quetiapine
AMY36467
DTXSID30881147
discontinued see: d288740
n-des[2-(2-hydroxyethoxy)ethyl]quetiapine

Research Excerpts

Effects

Excerpt	Reference	Relevance
"Norquetiapine has a specific effect on anxiety and depressive symptoms, showing a correlation between plasma concentrations and clinical efficacy only in patients with bipolar depression."	( Effect of quetiapine and norquetiapine on anxiety and depression in major psychoses using a pharmacokinetic approach: a prospective observational study. Altamura, AC; Bareggi, SR; Buoli, M; Dell'osso, B; Mauri, MC; Moliterno, D; Paletta, S, 2012)	1.4

Toxicity

Excerpt	Reference	Relevance
" Adverse events, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory tests were evaluated throughout the studies."	( Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. Davis, PC; Earley, WR; Hamer-Maansson, JE; Smith, MA; Winter, HR, 2008)	0.57
" Quetiapine was well tolerated, with no serious adverse events and no unexpected events reported."	( Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. Davis, PC; Earley, WR; Hamer-Maansson, JE; Smith, MA; Winter, HR, 2008)	0.57

Dosage Studied

Excerpt	Relevance	Reference
" The predictability in quetiapine concentration profiles for children aged 10 years to adults suggests that no dosage adjustment may be required when treating patients of these ages."	( Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. Davis, PC; Earley, WR; Hamer-Maansson, JE; Smith, MA; Winter, HR, 2008)	0.57

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
dibenzothiazepine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (28)

Assay ID	Title	Year	Journal	Article
AID1220273	Drug metabolism in human liver microsomes assessed as N-desalkylquetiapine sulfoxide formation at 3 uM after 30 mins by mass spectroscopy in presence of CYP2C19 inhibitor benzylnirvanol	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220285	Activity of cytochrome P450 in human liver microsomes by LC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220295	Activity of human CYP2D6 expressed in supersomes co-expressing cytochrome P450 reductase assessed as metabolite M3 formation after 60 mins by LC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220270	Drug metabolism in human liver microsomes assessed as 7-hydroxy-N-desalkylquetiapine formation at 3 uM after 30 mins by mass spectroscopy in presence of CYP2D6 inhibitor quinidine	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220274	Drug metabolism in human liver microsomes assessed as N-desalkylquetiapine sulfoxide formation at 3 uM after 30 mins by mass spectroscopy in presence of CYP2C9 inhibitor sulfaphenazole	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220275	Drug metabolism in human liver microsomes assessed as 7-hydroxy-N-desalkylquetiapine formation at 3 uM after 30 mins by mass spectroscopy in presence of CYP2C19 inhibitor benzylnirvanol	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220269	Activity of human CYP3A4 expressed in xenosomes assessed as intrinsic clearance per pmol protein by LC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220267	Activity of human CYP2D6 expressed in supersomes co-expressing cytochrome P450 reductase assessed as N-desalkylquetiapine sulfoxide formation after 60 mins by LC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220290	Activity of cytochrome P450 in human liver microsomes assessed as metabolite M3 formation by LC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220277	Drug metabolism in human liver microsomes assessed as N-desalkylquetiapine sulfoxide formation at 3 uM after 30 mins by mass spectroscopy	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220272	Drug metabolism in human liver microsomes assessed as 7-hydroxy-N-desalkylquetiapine formation at 3 uM after 30 mins by mass spectroscopy in presence of CYP1A2 inhibitor fluvoxamine	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220292	Drug metabolism in human liver microsomes assessed as 1 uM CYP3A4 inhibitor ketoconazole-mediated inhibition of N-desalkylquetiapine sulfoxide formation at 3 uM after 30 mins by mass spectroscopy	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220294	Drug metabolism in human liver microsomes assessed as CYP1A2 inhibitor fluvoxamine-mediated inhibition of 7-hydroxy-N-desalkylquetiapine formation at 3 uM after 30 mins by mass spectroscopy	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220276	Drug metabolism in human liver microsomes assessed as 7-hydroxy-N-desalkylquetiapine formation at 3 uM after 30 mins by mass spectroscopy in presence of CYP2C9 inhibitor sulfaphenazole	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220268	Activity of human CYP2D6 expressed in supersomes co-expressing cytochrome P450 reductase assessed as 7-hydroxy-N-desalkylquetiapine formation after 60 mins by LC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220286	Activity of cytochrome P450 in human liver microsomes assessed as 7-hydroxy-N-desalkylquetiapine formation measured as substrate inhibition constant by LC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220271	Drug metabolism in human liver microsomes assessed as N-desalkylquetiapine sulfoxide formation at 3 uM after 30 mins by mass spectroscopy in presence of CYP3A4 inhibitor ketoconazole	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220296	Activity of human CYP3A4 expressed in supersomes co-expressing cytochrome P450 reductase assessed as metabolite M3 formation after 60 mins by LC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220265	Activity of human CYP3A4 expressed in supersomes co-expressing cytochrome P450 reductase assessed as N-desalkylquetiapine sulfoxide formation after 60 mins by LC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220284	Activity of cytochrome P450 in human liver microsomes assessed as N-desalkylquetiapine sulfoxide formation measured as low-affinity/high-capacity binding constant by LC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220291	Drug metabolism in human liver microsomes assessed as 5 uM CYP2D6 inhibitor quinidine-mediated inhibition of 7-hydroxy-N-desalkylquetiapine formation at 3 uM after 30 mins by mass spectroscopy	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220262	Activity of human CYP3A4 expressed in xenosomes assessed as substrate depletion after 60 mins by LC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220293	Drug metabolism in human liver microsomes assessed as 1 uM CYP3A4 inhibitor ketoconazole-mediated inhibition of metabolite M3 formation at 3 uM after 30 mins by mass spectroscopy	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220264	Drug metabolism in human liver microsomes assessed as 7-hydroxy-N-desalkylquetiapine formation at 3 uM after 30 mins by mass spectroscopy	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220263	Activity of human CYP2D6 expressed in supersomes co-expressing cytochrome P450 reductase assessed as substrate depletion after 60 mins by LC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220283	Activity of cytochrome P450 in human liver microsomes assessed as N-desalkylquetiapine sulfoxide formation measured as high-affinity/low-capacity binding constant by LC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220261	Activity of human CYP2D6 expressed in supersomes co-expressing cytochrome P450 reductase assessed as intrinsic clearance per pmol protein by LC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1346971	Human NET (Monoamine transporter subfamily)	2008	Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Sep, Volume: 33, Issue:10	N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (10.53)	29.6817
2010's	14 (73.68)	24.3611
2020's	3 (15.79)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	40.63 (24.57)
Research Supply Index	3.14 (2.92)
Research Growth Index	5.54 (4.65)
Search Engine Demand Index	56.46 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (40.63)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (15.79%)	5.53%
Reviews	1 (5.26%)	6.00%
Case Studies	1 (5.26%)	4.05%
Observational	0 (0.00%)	0.25%
Other	14 (73.68%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	2.17	1	0	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
quetiapine [no description available]	2.04	1	0	dibenzothiazepine; N-alkylpiperazine; N-arylpiperazine	adrenergic antagonist; dopaminergic antagonist; histamine antagonist; second generation antipsychotic; serotonergic antagonist
reboxetine Reboxetine: A morpholine derivative that is a selective and potent noradrenaline reuptake inhibitor; it is used in the treatment of DEPRESSIVE DISORDER.	2.17	1	0	aromatic ether
raclopride Raclopride: A substituted benzamide that has antipsychotic properties. It is a dopamine D2 receptor (see RECEPTORS, DOPAMINE D2) antagonist.	4.37	1	1	salicylamides
fluvoxamine Fluvoxamine: A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.. fluvoxamine : An oxime O-ether that is benzene substituted by a (1E)-N-(2-aminoethoxy)-5-methoxypentanimidoyl group at position 1 and a trifluoromethyl group at position 4. It is a selective serotonin reuptake inhibitor that is used for the treatment of obsessive-compulsive disorder.	2.07	1	0	(trifluoromethyl)benzenes; 5-methoxyvalerophenone O-(2-aminoethyl)oxime	antidepressant; anxiolytic drug; serotonin uptake inhibitor
neuropeptide y Neuropeptide Y: A 36-amino acid peptide present in many organs and in many sympathetic noradrenergic neurons. It has vasoconstrictor and natriuretic activity and regulates local blood flow, glandular secretion, and smooth muscle activity. The peptide also stimulates feeding and drinking behavior and influences secretion of pituitary hormones.	3.46	1	1
quetiapine fumarate Quetiapine Fumarate: A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER.	8.57	16	3	fumarate salt

Condition	Relationship Strength	Studies	Trials
Depression, Endogenous [description not available]	2.04	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.48	2	0
Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.	2.04	1	0
Adipocere [description not available]	2.25	1	0
Electrocardiogram QT Prolonged [description not available]	2.25	1	0
Long QT Syndrome A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.	2.25	1	0
Affective Psychosis, Bipolar [description not available]	3.48	2	0
Depression, Involutional Form of depression in those MIDDLE AGE with feelings of ANXIETY.	2.52	2	0
Bipolar Disorder A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.	3.48	2	0
Depressive Disorder, Major Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)	2.52	2	0
Dementia Praecox [description not available]	3.87	2	1
Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.	7.48	2	0
Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.	8.87	2	1
Anhedonia Inability to experience pleasure due to impairment or dysfunction of normal psychological and neurobiological mechanisms. It is a symptom of many PSYCHOTIC DISORDERS (e.g., DEPRESSIVE DISORDER, MAJOR; and SCHIZOPHRENIA).	7.11	1	0
Innate Inflammatory Response [description not available]	2.11	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	7.11	1	0
Psychoses [description not available]	7.46	2	0
Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.	7.07	1	0
Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)	7.46	2	0

chemdatabank.com